FDA Accepts biologics license application for DYNE-251, Alzheimer's Association Launches PROTECT-Cog, NeurologyLive Produces Multiple Feature Length Pieces

WATCH TIME: 5 minutes | Captions are auto-generated and may contain errors.

Below is a transcript of the video.

Welcome to the Neurology News Network, my name is Louie Pasculli and here’s a look at some of the top stories in Neurology.

Beginning with FDA news, the administration has accepted for review the biologics license application (BLA) for zelecimentrostudirsen (z-rostudirsen, also known as DYNE-251) for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.¹The agency granted Priority Review and set a PDUFA target action date of January 21, 2027. Dyne Therapeutics continues to expect a potential U.S. launch in the first quarter of 2027, assuming approval on the anticipatedtimeline.¹

John Cox, president and chief executive officer of Dyne, said in a statement¹, "This milestone represents significant progress toward our goal of delivering functional improvement for those living with DMD amenable to exon 51 skipping. With z-rostudirsen, we set out to advance the treatment paradigm in DMD by combining a robust increase in near-full length dystrophin with broad delivery to relevant tissues."

The submission seeks Accelerated Approval based on dystrophin as a surrogate endpoint, a pathway already established for other exon-skipping therapies in DMD.

In other news, the Alzheimer's Association announced the launch of the PROTECT-Cog Study (Prevention of Risk for cognitive decline through Combined Therapy) at the 2026 Alzheimer's Association International Conference (AAIC) in London. The global trial will evaluate whether combining a multidomain lifestyle intervention with a metabolism-targeting drug, such as a GLP-1 receptor agonist, further reduces cognitive decline risk beyond what lifestyle intervention alone has shown.²

"PROTECT-Cog builds directly on what we learned from U.S. POINTER and takes the next critical step in prevention science," Maria C. Carrillo, PhD, chief science officer and medical affairs lead at the Alzheimer's Association and principal investigator of the study, said in a statement.² "By testing a combined approach that targets both lifestyle and biology, we have the opportunity to better understand how to meaningfully reduce the risk of cognitive decline before symptoms begin."

The study extends the Association's existing prevention infrastructure, built through U.S. POINTER, LatAm FINGERS, and the World-Wide FINGERS Network. "The Alzheimer's Association is uniquely positioned to lead this next generation of dementia prevention research," Heather M. Snyder, PhD, senior vice president of medical and scientific relations at the Association and staff lead on the project, said in a statement.²

Over the past week, NeurologyLive® has been busy producing several feature pieces spanning multiple disciplines across neurology, from brain health and injury in soccer players to emerging therapies, clinical trials, and advances in Alzheimer disease research. Across these features, experts offered insights into new treatment approaches, the complex pathways underlying neurologic disease, advances in diagnosis and biomarker development, and the evolving research landscape.

In a special report filmed at the 2026 Alzheimer’s Association International Conference (AAIC), Yogesh Shah, MD, MPH, FAAFP, discussed the importance of understanding how amyloid pathology develops years before symptoms emerge and how advances in blood-based biomarkers could help build the foundation for earlier Alzheimer disease diagnosis. Meanwhile, The Hidden Cost of the Beautiful Game, presented in 2 parts, explored the potential long-term neurologic and mental health effects associated with repetitive head impacts in soccer, bringing together perspectives from clinicians and researchers on brain injury, brain health, and the need to better understand the potential long-term effects facing athletes.

Our coverage also examined the evolving therapeutic landscape for fragile X syndrome in Advances in Fragile X Syndrome Therapeutics: Overviewing the Pipeline, highlighting emerging treatment strategies aimed at addressing the complex cognitive, behavioral, and functional symptoms associated with the condition. The feature explored the current pipeline and the potential for novel approaches to address longstanding unmet needs for patients and their families.

In honor of World Brain Day, NeurologyLive also took an in-depth look at emerging strategies to protect brain health and prevent neurologic disease. From modifiable risk factors and lifestyle interventions to advances in early detection and disease prevention, the coverage highlighted the growing recognition that maintaining brain health requires a multidimensional approach across the lifespan.

Together, these stories highlight the breadth of ongoing innovation across neurology and the continued push toward earlier diagnosis, more precise treatment, improved prevention strategies, and better outcomes for patients. To read the full pieces and to get more direct access to expert insight, head to NeurologyLive.com. Be sure to tune in next week to remain informed on the latest in neurology. I’m Louie Pasculli, thanks for watching Neurology News Network.

REFERENCES
1. Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD). News release. Dyne Therapeutics. July 20, 2026. Accessed July 20, 2026. https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-us-fda-acceptance-biologics-license
2. Alzheimer's Association launches "PROTECT-Cog" study to test U.S. POINTER lifestyle and GLP-1 or similar drug to cut risk of cognitive decline. News release. Alzheimer's Association. July 13, 2026. Accessed July 16, 2026. https://www.prnewswire.com/news-releases/alzheimers-association-launches-protect-cog-study-to-test-us-pointer-lifestyle-and-glp-1-or-similar-drug-to-cut-risk-of-cognitive-decline-302823408.html